Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of t...
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
MDPI AG
2020-07-01
|
| Edice: | Journal of Cardiovascular Development and Disease |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2308-3425/7/3/25 |